Altogether, such data led us to hypothesize that the IDO1/KP pathway could preferentially contribute to the immune-suppressive phenotype of STS cells and be an important mechanism of the primary resistance to PD1 inhibition observed in sarcoma patients (8), and that targeting this pathway with an innovative compound would improve anti-PD1/PDL1 efficacy in this setting. This evidence concerns the gene CD274 and sarcoma.